Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
IFEX w. MESNEX COMBINATION PACK |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Alkylating agent + uroprotectant. |
| Generic Name |
|
Ifosfamide 1g, 3g; per vial; pwd for IV infusion after reconstitution, + mesna 1g/vial. |
| Also |
|
• IFEX
|
| Indications |
|
Third-line adjunctive treatment of germ cell testicular cancer. |
| Children |
|
Not recommended. |
| Adults |
|
Give by slow IV infusion over at least 30 minutes. 1.2g/m2 per day for 5 consecutive days; repeat every 3 weeks or after hematological recovery (platelets ≥100000/microliter, WBC ≥ 4000/microliter). |
| Contraindications |
|
Severe bone marrow depression. |
| Precautions |
|
Discontinue if neurologic effects (eg, somnolence, confusion, hallucinations) occur. Do urinalysis before each dose, postpone dose if hematuria occurs. Give mesna and at least 2L fluids daily. Do hematologic profile before each dose; discontinue if WBCs <2000/microliter or platelets <50000/microliter. May interfere with wound healing. Impaired hepatic, renal, or hematopoetic function. Prior radiation therapy or other cytotoxic agents. Ensure adequate hydration. Pregnancy (Cat.D). Nursing mothers: not recommended. |
| Interactions |
|
Increased risk of myelosuppression with other chemotherapy agents. |
| Adverse Reactions |
|
Alopecia, GI upset, hematuria, CNS toxicity, infection, renal or liver dysfunction, phlebitis, fever, urotoxicity (eg, hemorrhagic cystitis), leukopenia, thrombocytopenia. |
| How Supplied |
Ifex single-dose vials—1
Combination Pack w. Mesnex:
Ifex 5x1g single-dose vials + Mesnex 3x1g multidose vials
Ifex 10x1g single-dose vials + Mesnex 10x1g multidose vials
Ifex 2x3g single-dose vials + Mesnex 6x1g multidose vials |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
